Idorsia (OTCPK:IDRS.F) FY Conference Transcript

Summary of Idorsia's Conference Call Company Overview - Company: Idorsia - Key Products: - QUVIVIQ: A dual orexin receptor antagonist for insomnia - TRYVIO (also known as JERAYGO): An endothelin receptor antagonist for systemic hypertension - Pipeline: Built on the legacy of Actelion, with a focus on drug discovery and development Financial Position - Debt Restructuring: Successfully restructured debt situation, leading to an unencumbered equity story for Idorsia [3] - Sales Performance: - QUVIVIQ sales in 2025 reached CHF 134 million, outperforming the guidance of CHF 130 million [6] - Outlook for 2026 sales is around CHF 200 million [6] QUVIVIQ Insights - Geographic Performance: - Strong growth in Europe and Canada, with a focus on reimbursement strategies [5] - Notable uptake in Japan, where DORA class accounts for 37% of the insomnia market [4] - In China, 300,000-400,000 patients on QUVIVIQ within the first six months of launch [4] - Market Strategy: - Focus on neurologists and psychiatrists initially, followed by general practitioners (GPs) for broader adoption [8] - Co-promotion partnerships in Europe to enhance market access [8] U.S. Market Challenges - Scheduling Issues: QUVIVIQ is the third DORA approved by the FDA, facing scheduling challenges due to historical precedents [9][10] - Citizen Petition: Submitted to the FDA in April 2023 to address scheduling concerns based on global usage data showing no abuse potential [11][12] Pediatric Data - Pediatric Program: Phase 2 dose-finding study for pediatric insomnia expected to report results in Q1 or Q2 2024 [14] - Potential Impact: Positive outcomes could support descheduling efforts and improve access for children with sleep disorders [16] Lucerastat for Fabry Disease - Product Overview: Oral substrate reduction therapy with advantages over enzyme replacement therapies [17] - Clinical Development: Pivotal trial design includes a renal function study based on eGFR [18] - Market Position: Positioned as a broadly applicable treatment for Fabry disease, with potential expansion into other lysosomal storage diseases [19] TRYVIO (JERAYGO) Updates - Approval Status: Approved in the U.S. and Europe for systemic hypertension [27] - Differentiation: Unique profile with no signals for hyperkalemia or hyponatremia, applicable to patients inadequately controlled on other therapies [27][28] - Partnership Strategy: Seeking partnerships to maximize value, particularly in cardiology and nephrology [30][31] Pipeline Developments - CCR6 Antagonist: Initiated proof of concept study in psoriasis, with potential for expansion into other T helper 17 mediated diseases [34][35] - CXCR7 for Progressive MS: Trial initiation expected soon, focusing on anti-inflammatory and remyelinating benefits [36] - CXCR3 for Vitiligo: Aiming to disrupt melanocyte targeting, with plans to initiate trials later this year [41][42] Conclusion - Overall Strategy: Idorsia is focused on leveraging its unique product offerings and pipeline to create value, while navigating financial challenges and market dynamics [44]